logo
RAD Residential Unveils RADCam: The World's First AI Security Camera with Real-Time Emergency Response

RAD Residential Unveils RADCam: The World's First AI Security Camera with Real-Time Emergency Response

Yahoo08-05-2025

Detroit, Michigan, May 07, 2025 (GLOBE NEWSWIRE) -- RAD Residential, a subsidiary of Artificial Intelligence Technology Solutions, Inc. (OTCPK: AITX), today announced the official launch of RADCam, the first consumer-grade security camera engineered to autonomously challenge intruders, engage with visitors, and initiate emergency response in real time. Developed for modern home protection, RADCam transforms security from passive surveillance to active intervention.
RADCam features AI-powered behavior recognition and smart notifications for proactive home and business security.
Unlike conventional cameras that only record, RADCam identifies credible threats and initiates immediate response protocols through its proprietary SOS emergency feature. This capability enables the system to issue a verbal warning and escalate to emergency contacts or security providers in under 60 seconds, offering a faster response than traditional alarms or motion sensors.
'Traditional cameras watch. RADCam protects,' said Steve Danelon, President of RAD Residential. 'With real-time threat response and instant escalation, we've reimagined what home security should be—proactive, not passive.'
Real-Time Protection Through AI-Powered Engagement
Real-Time Threat Detection
RADCam interprets human behavior patterns—not just motion. The system identifies lingering or suspicious activity and responds with voice prompts designed to deter intrusions before they occur.
Intelligent Voice Deterrence
With human-like voice interaction, RADCam verbally challenges potential threats and reinforces that the property is actively monitored and protected.
Sub-Minute SOS Activation
Within seconds of detecting a credible threat, RADCam can deliver a verbal warning and initiate emergency escalation to a homeowner, private security provider, or local authorities, depending on configuration.
Smart Modes for All Situations
Concierge Mode: Greets guests and couriers during daytime hours with a welcoming tone.
Security Mode: Activates after-hours and escalates threats with assertive deterrent messaging.
Quiet Mode: Operates silently while still sending real-time alerts and recording events.
Built for the Future of Residential and Commercial Security
Developed in Detroit by a team of AI and private security professionals, RADCam functions as a standalone, AI-powered security solution and is available through Amazon.com, Walmart.com, B&H Photo, and www.radcam.ai. RAD Residential is also preparing to launch a commercial version of the device, internally referred to as "ROSA Lite." This upcoming release will incorporate RADCam's real-time threat detection, voice intervention, and SOS capabilities into small business, retail, and enterprise environments. ROSA Lite is built on SARA™, RAD's advanced AI analytics platform.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

H.C. Wainwright Reiterates Buy Rating on Immix Biopharma (IMMX) Following Promising Interim Results from NXC-201 Trial
H.C. Wainwright Reiterates Buy Rating on Immix Biopharma (IMMX) Following Promising Interim Results from NXC-201 Trial

Yahoo

time36 minutes ago

  • Yahoo

H.C. Wainwright Reiterates Buy Rating on Immix Biopharma (IMMX) Following Promising Interim Results from NXC-201 Trial

On June 4, analyst Robert Burns of H.C. Wainwright reiterated a Buy rating on Immix Biopharma, Inc. (NASDAQ:IMMX) with a price target of $7.00. The analyst based the rating on the promising interim results from the NEXICART-2 Phase 1/2 clinical trial of NXC-201, presented at the 2025 American Society of Clinical Oncology Annual Meeting (ASCO 2025) in Chicago, Illinois. The trial assessed the efficacy of NXC-201 in patients with relapsed/refractory AL amyloidosis and delivered a 100% response rate, with a considerable portion attaining a complete hematologic response. The analyst reasoned that the absence of hematologic relapse or progression and the rapid mean time to response further highlight NXC-201's potential as a viable treatment. A doctor in a white coat discussing clinical trial results with a patient in an oncology practice. Burns also reasoned that NXC-201 appears to have a favorable safety profile, as no patients experienced severe cytokine release syndrome or neurotoxicity. While he highlighted the need for longer-term follow-up and the small sample size, the analyst stated that the interim results are promising when compared to existing treatments. This condition does not have FDA-approved agents, and there exists a fragmented treatment landscape post-frontline therapy, factors that suggest the notable market opportunity for NXC-201 and support the buy rating for Immix Biopharma, Inc. (NASDAQ:IMMX). Immix Biopharma, Inc. (NASDAQ:IMMX) is a biopharmaceutical company that develops therapies for inflammatory diseases and cancer. While we acknowledge the potential of IMMX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Sign in to access your portfolio

Jefferies Maintains Buy Rating on Rhythm Pharmaceuticals (RYTM), Sets $80 Price Target
Jefferies Maintains Buy Rating on Rhythm Pharmaceuticals (RYTM), Sets $80 Price Target

Yahoo

time36 minutes ago

  • Yahoo

Jefferies Maintains Buy Rating on Rhythm Pharmaceuticals (RYTM), Sets $80 Price Target

In a report released on June 4, Dennis Ding from Jefferies maintained a Buy rating on Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) with a price target of $80.00. The analyst based the rating on the company's strategic developments and promising pipeline. One of the primary reasons behind the rating was the anticipated Phase II data for the oral treatment for hypothalamic obesity (HO). It is expected to deliver notable BMI reduction and has been de-risked, thereby extending the potential of the franchise beyond the current expiration dates. A scientist conducting research in a laboratory, studying a Petri dish with advanced biopharmaceuticals. The analyst stated that management is confident in the weekly subcutaneous (subQ) treatment, which closely aligns with the previously approved setmelanotide, and thus further adds to the positive outlook for Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM). According to Ding, the setmelanotide Phase II open-label trial for Prader-Willi Syndrome can also pave the way for a significant opportunity if successful, even after its previous challenges. Management is focusing on patient starts instead of the immediate revenue post-launch, and this strategy supports the long-term growth prospects, according to the analyst. Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) is a commercial-stage biopharmaceutical company that develops and commercializes therapeutics for the treatment of rare diseases. Its product pipeline includes IMCIVREE (setmelanotide), a precision medicine that treats hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. The company also has other programs, including a preclinical suite of investigational candidates to treat congenital hyperinsulinism and a clinical development program for setmelanotide in other rare MC4R pathway diseases. While we acknowledge the potential of RYTM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None.

H.C. Wainwright Initiates Coverage of Akebia Therapeutics (AKBA) With Buy Rating
H.C. Wainwright Initiates Coverage of Akebia Therapeutics (AKBA) With Buy Rating

Yahoo

time36 minutes ago

  • Yahoo

H.C. Wainwright Initiates Coverage of Akebia Therapeutics (AKBA) With Buy Rating

Matthew Caufield, an analyst from H.C. Wainwright, initiated coverage of Akebia Therapeutics, Inc. (NASDAQ:AKBA) with a Buy rating and a $8 price target, on June 4. The analyst gave the optimistic rating due to the company's VAFSEO product and its potential in the CKD anemia market. VAFSEO is an approved treatment for anemia in adults with chronic kidney disease on dialysis. According to the analyst, the treatment is gaining considerable momentum among dialysis organizations, and this trend is anticipated to support near-term growth. He expects VAFSEO's ongoing launch to offset the effect of generics on AURYXIA, another product by Akebia Therapeutics, Inc. (NASDAQ:AKBA) that deals with hyperphosphatemia. A biopharmaceutical team in a laboratory analyzing new compounds to develop therapeutics. The analyst also reasoned that Akebia Therapeutics, Inc. (NASDAQ:AKBA) is positioned for success as it has secured contracts that cover almost all dialysis patients in the US. VAFSEO offers flexibility in its dosing regimen, ranging from 150mg to 600mg, making it a factor that allows for personalized treatment and potentially growing prescriptions. Caufield pointed out VAFSEO's oral administration as another reason supporting the optimistic rating, giving it an advantage over existing therapies, such as iron supplementation and erythropoiesis-stimulating agents. Akebia Therapeutics, Inc. (NASDAQ:AKBA) is a biopharmaceutical company that develops and commercializes drugs to treat metabolic and renal diseases. While we acknowledge the potential of AKBA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store